Compounded Tirzepatide Providers Compared (2026)

Is compounded tirzepatide still legal in 2026?

Yes — but the legal basis is narrower than it was in 2024. Tirzepatide was removed from the FDA shortage list in December 2024. That ended the broad shortage exemption that allowed large-scale 503B outsourcing facilities to compound it without a patient-specific prescription. The FDA gave 503B facilities until March 19, 2025 to wind down those programs, and courts declined to block the deadline.

What remains is the 503A individual-patient pathway. A state-licensed 503A pharmacy may still compound tirzepatide for a specific, identified patient when there is a documented clinical reason the FDA-approved versions — Zepbound and Mounjaro — will not work for that person. A common documented reason is an allergy to an inactive ingredient in the commercial formulation. Compounding purely because it is cheaper is not a qualifying reason under the current rule.

One pending development: on April 30, 2026, FDA proposed removing tirzepatide from the 503B bulk substances list entirely, with a public comment period running through June 29, 2026. That proposal concerns 503B bulk compounding, which has already wound down in practice. It does not change the existing 503A rules. No final rule has been issued as of this writing.

• 503B bulk compounding of tirzepatide: ended March 19, 2025 — no longer permitted.
• 503A individual-patient compounding: still legal when a prescriber documents a valid clinical reason for a specific patient.
• Compounding to save money alone does not qualify as a clinical reason under current FDA guidance.
• The April 30, 2026 FDA proposal targets 503B only and has not become a final rule.

503A vs 503B: why the distinction matters for your program

Every provider on this page operates under 503A — the individual-patient track — because 503B bulk compounding of tirzepatide is no longer available. Understanding the difference helps you evaluate what you are actually buying.

A 503A pharmacy compounds medication after receiving a valid prescription for a named patient. The prescription must come from a licensed prescriber who has determined there is a legitimate clinical need the commercially available drug cannot meet. The compounded product is not FDA-approved as a finished drug — it has not gone through the same manufacturing, sterility and consistency testing that Zepbound and Mounjaro have. That is a meaningful difference from the brand, not a technicality.

A 503B outsourcing facility, by contrast, could compound in larger quantities without patient-specific prescriptions when a drug was on the shortage list. That pathway is closed for tirzepatide. If a provider implies they operate under some other compounding exemption for tirzepatide in 2026, that is a claim worth pressing them on with specifics.

• Ask your provider: which licensed 503A pharmacy fills your prescription, and is it accredited by PCAB or a state board?
• Compounded tirzepatide is NOT FDA-approved — 'compounded' and 'FDA-approved' are mutually exclusive by definition.
• Your telehealth prescriber should review labs, document your clinical need, and be reachable if you have side effects — not just click a box.
• Additives such as B12 or L-carnitine in some compounded formulations are not present in the FDA-approved brand and have not been independently evaluated for safety when combined with tirzepatide.

Compounded tirzepatide provider breakdown

Curex — lowest all-in price with no membership

Curex holds the lowest verified price we can confirm: roughly $199 a month all-in, with medication, the online consult, shipping and follow-up dose adjustments folded into that one number. There is no separate membership fee sitting beside it, which is rarer than it should be in this category. That transparency is the core of the pitch.

The caveat is the word "from." The $199 is starter-dose language, and Curex does not publish a clear maintenance-dose price ladder. Some women will titrate to a higher dose over the course of treatment, and the price at that dose is the one to pin down. Ask for the full dose-by-dose price schedule in writing before you enroll.

• Pros — lowest verified all-in price; no separate membership; medication, consult and shipping bundled.
• Cons — maintenance-dose pricing is not publicly posted; confirm before committing to the program.

Mochi Health — flat medication price at every dose

Mochi prices its tirzepatide medication at a flat $199 a month regardless of dose, which is a genuine advantage as you titrate up — you won't hit a price hike at 5mg or 7.5mg. The piece the homepage presents quietly is the membership: about $79 a month, billed separately, which covers care coordination and clinician access. Add both and the real cost is roughly $278 a month.

For a woman who expects a long titration, a flat medication fee that never climbs can work out cheaper than a rival with a lower starting price that hikes with each dose step. The math favors Mochi over some "no-membership" programs once you're past the starter dose. Just price the two lines together every time you evaluate it.

• Pros — flat $199 medication fee at any dose; obesity-medicine physicians; shipping included.
• Cons — separate ~$79/mo membership means the real all-in is ~$278, not the advertised $199.

Eden — no membership, flat across doses

Eden sits in the honest middle of the range: no membership fee, the same rate whatever your dose, and a modest first-month discount. Expect roughly $249 to start and about $329 to $349 a month ongoing. Sources differ by a small amount on the exact ongoing figure, which is common in this category — the live price on the checkout page is what matters, and it is worth confirming before you commit.

• Pros — no separate membership; flat rate across all dose tiers; clear first-month-then-ongoing structure.
• Cons — ongoing rate (~$329–$349) is higher than Curex; exact figure varies slightly by source and plan.

Peak Wellness — watch the first-month vs ongoing rate

Peak Wellness offers flat-dose pricing with no per-tier hikes, which is a real convenience during titration. The number to watch carefully is the timeline: the roughly $229 figure that draws attention is an intro or annual-plan rate. From the second month onward — or on a month-to-month plan — the price steps up to about $349. That $349 flat rate is still fair; it just isn't the introductory number. Budget for the standing rate, not the teaser.

• Pros — one flat price regardless of dose; no membership fee; straightforward 503A structure.
• Cons — the low ~$229 intro rate steps up to ~$349 ongoing; confirm which rate your plan locks in.

Fridays — bundled coaching and dietitian support

Fridays is priced as a program rather than a standalone prescription. Compounded tirzepatide runs roughly $299 a month on a 12-month plan and up toward $389 on shorter terms, with coaching, a registered dietitian and 24/7 messaging folded in. There is also a microdose option around $198 a month for those who want to start at a lower dose. If you would otherwise pay for coaching separately, the all-in bundle reads better than the bare medication number.

• Pros — coaching, dietitian and app bundled; lower monthly rate on a 12-month commitment; microdose track available.
• Cons — higher entry price than Curex or Mochi at comparable support levels; best rate requires a long commitment.

Willow — flat $399 in 33 states

Willow keeps its structure simple: a flat $399 a month at every dose, with telehealth and shipping included, and no separate membership. The constraint is geography — the program is currently available in 33 states. If you live in a covered state and want a single predictable number that will not change as you titrate, Willow delivers that. Check the state list before you go through intake.

• Pros — flat price at every dose; single all-in bill; no membership fee.
• Cons — only available in 33 states; higher than the cheapest 503A providers at $399/mo flat.

Henry Meds — oral or injectable, fully bundled

Henry Meds is one of the few programs offering tirzepatide as an oral tablet alongside the standard injection, which matters for women who prefer to avoid needles. Oral tirzepatide runs about $349 a month and the injection about $449, with visits, supplies and shipping bundled into one price and no long-term commitment — a monthly plan you can cancel. It is not the cheapest option here, but the oral format and the all-in simplicity are genuine differentiators.

• Pros — oral and injectable formats; visits, supplies and shipping all bundled; monthly plan with no lock-in.
• Cons — at $349–$449 it is the highest range on this list; the cheaper Henry Meds headlines you'll see elsewhere refer to its semaglutide, not tirzepatide.

What to check before you enroll in any compounded tirzepatide program

The monthly price is where most comparisons start and stop, but it is not the whole picture. A few minutes of due diligence before you hand over payment details can save you a rude surprise on the second bill.

• Read the all-in number, not the sticker — ask whether the price includes shipping, the consult, supplies and follow-up messages, or whether any of those are billed separately.
• Clarify intro versus ongoing — a discounted first month is bait, not your standing cost; ask what month two and month six will cost.
• Ask for the dose ladder in writing — programs that quote a starter dose without publishing higher-dose pricing may charge substantially more as you titrate.
• Confirm the pharmacy — a legitimate 503A program can name the pharmacy that fills your prescription; accreditation by PCAB or a state board is a positive sign.
• Check the billing cycle — programs that bill every 28 days charge you 13 times a year, not 12; that alone adds about 8 percent to whatever monthly figure you were quoted.
• Understand cancellation — some multi-month prepay plans are non-refundable; know the terms before you commit to a three-month block.

Compounded tirzepatide and perimenopause: what to know

Weight that accumulates in your forties and fifties often tracks hormonal shifts rather than a simple change in calories. Estrogen decline changes where and how your body stores fat, and insulin sensitivity typically worsens in the perimenopause years — both factors that make weight management harder through diet alone. Tirzepatide works on both GLP-1 and GIP receptors, which gives it a dual mechanism that has produced meaningfully stronger average weight loss in trials than single-receptor GLP-1 drugs.

That said, a GLP-1 prescription is one tool, not a complete plan. The programs with bundled coaching or dietitian access — Fridays in particular — may offer real value for perimenopausal women who want support navigating the hormonal picture alongside the medication. If the hormonal context itself is as important to you as the weight piece, it is worth asking any provider whether their clinicians have specific experience with perimenopause, not just general weight management.